从医疗“三重目标”看门冬胰岛素30的患者获益

摘要

理想的医疗应该是“三重目标”(疗效、患者体验与费用)的实现，尤其是糖尿病等慢性病。作为糖尿病治疗手段之一的胰岛素，与预混人胰岛素相比，门冬胰岛素30在实现这三重目标上更有优势，具体体现在能有效地降低血糖、减少低血糖风险，且患者依从性好、长期费用更节省等方面，多重临床获益逐步被广泛认可。本文以“三重目标”为出发点，比较了门冬胰岛素30与预混人胰岛素的患者获益。%The ideal medicine are proposed to reach the triple aims (health, care and cost), with no exception on chronic diseases such as diabetes. As insulin for medication on diabetes, biphasic insulin aspart 30 gains advantage over biphasic human insulin, on multiple aspects such as glucose lowering, reduced risk of hypoglycemia, improvement of patients experience and long-term cost savings, which gain more recommendations and acceptance for patents' benefit gain. This review differentiated benefit gain between biphasic insulin aspart 30 and biphasic human insulin, as well as achievement on triple aims of medicine.